[vc_row css=”.vc_custom_1522131095591{padding-bottom: 30px !important;}”][vc_column][vc_column_text]Advanced Enzyme Technologies Limited (Advanced Enzymes; NSE: ADVENZYMES; BSE: 540025), a leading speciality biotech company, with global leadership in the manufacturing of enzymes, today announced that its wholly owned subsidiary Advanced Enzymes Europe B.V. has entered into a binding agreement with Germany based Evoxx Technologies GmbH, to acquire a 100% stake for a consideration of € 7.65 million.
V.L. Rathi, Chairman, Advanced Enzymes, said, “Evoxx has a great strategic fit for us. With
Evoxx we significantly expand our R&D capabilities, and also strengthen our European presence.”
Evoxx Technologies GmbH is an industrial biotech company focused on the development & production of industrial enzymes, as well as a few specialized carbohydrates for nutritional applications. Evoxx was founded as evocatal GmbH in 2006, and has a team of 35+ scientists & technicians across two sites in Germany.
Click to View PDF[/vc_column_text][/vc_column][/vc_row][vc_row full_width=”stretch_row” bg_type=”image” parallax_style=”vcpb-default” bg_image_new=”id^1823|url^https://advancedenzymes.us/wp-content/uploads/2016/02/footer-form-banner.jpg|caption^null|alt^null|title^footer-form-banner|description^null” bg_img_attach=”fixed” bg_override=”full” enable_overlay=”enable_overlay_value” overlay_color=”rgba(10,10,10,0.72)” overlay_pattern=”09.png” overlay_pattern_attachment=”fixed” css=”.vc_custom_1522130726839{margin-bottom: -60px !important;padding-top: 50px !important;padding-bottom: 40px !important;}”][vc_column]
